In our work, using a syngeneic orthotopic grafting model of breast cancer, the absence of tenascin-C production by tumor cells was compensated by CAF-derived tenascin-C, meaning that total tumor levels of this matrix protein were not altered when grafting tumors with high or low tenascin-C expression levels. Here, TNC is linked to neoplasm.